MedPath

Hydrocodone

Generic Name
Hydrocodone
Brand Names
Dalmacol, Hycet, Hycodan, Hydromet, Hysingla, Lorcet, Lortab, Norco, Obredon, Reprexain, Tussicaps, Tussionex, Vicoprofen, Xodol, Zamicet, Zohydro, Zydone
Drug Type
Small Molecule
Chemical Formula
C18H21NO3
CAS Number
125-29-1
Unique Ingredient Identifier
6YKS4Y3WQ7
Background

Hydrocodone is a synthetic opioid derivative of codeine. It is commonly used in combination with acetaminophen to control moderate to severe pain. Historically, hydrocodone has been used as a cough suppressant although this has largely been replaced by dextromethorphan in current cough and cold formulations. Hydrocodone's more potent metabolite, hydromorphone has also found wide use as an analgesic and is frequently used in cases of severe pain. The FDA first approved Hydrocodone for use as part of the cough suppressant syrup Hycodan in March of 1943.

Indication

Hydrocodone is indicated for the management of acute pain, sometimes in combination with acetaminophen or ibuprofen, as well as the symptomatic treatment of the common cold and allergic rhinitis in combination with decongestants, antihistamines, and expectorants.

Associated Conditions
Acute Pain, Chronic Pain, Cough, Cough caused by Allergic Rhinitis, Cough caused by Common Cold, Nasal Congestion caused by Allergic Rhinitis, Nasal Congestion caused by Common Cold, Rhinitis caused by Common Cold, Severe Pain, Moderate Pain, Upper respiratory symptoms caused by Allergic Rhinitis, Upper respiratory symptoms caused by Common Cold
Clinical Trials
Related News

Teen Substance Use Remains at Historic Lows in 2024, NIH Survey Reveals

• Substance use among adolescents has maintained historically low levels for the fourth consecutive year following significant declines during the COVID-19 pandemic, according to the latest NIH-funded Monitoring the Future survey. • Alcohol, nicotine vaping, and cannabis remain the most commonly reported substances among teens, with 67.1% of 12th graders reporting complete abstinence from these substances in the past 30 days, up from 62.6% in 2023. • Researchers describe the sustained reduction in teen substance use as "unprecedented," with particularly notable decreases in prescription narcotic misuse among 12th graders reaching an all-time low of 0.6%, down from 9.5% in 2004.

FDA Approves Test to Identify Patients at Risk of Opioid Use Disorder

The FDA has approved the AvertD test, a DNA analysis tool designed to identify patients at risk of developing opioid use disorder before they are prescribed opioid analgesics. This approval comes as part of efforts to combat the ongoing opioid epidemic in the US.

FDA Approves Journavx, a Novel Non-Opioid Painkiller, Offering New Hope for Acute Pain Management

• The FDA has approved Journavx (suzetrigine), a first-in-class non-opioid analgesic, for treating moderate to severe acute pain in adults, offering a safer alternative to opioids. • Journavx works by selectively blocking pain signals in the peripheral nervous system, reducing pain without the addictive potential and severe side effects associated with opioids. • Clinical trials demonstrated Journavx's effectiveness in reducing pain after surgeries, with a safety profile comparable to placebo, though it didn't outperform opioid-acetaminophen combinations. • Priced at $15.50 per pill, Journavx faces challenges in accessibility due to its higher cost compared to generic opioids, but it represents a significant step in combating the opioid crisis.

Vertex's Non-Opioid Pain Drug VX-548 Achieves Positive Phase 3 Results

• Vertex Pharmaceuticals' VX-548 demonstrated statistically significant pain reduction compared to placebo in Phase 3 trials for acute pain following abdominoplasty and bunionectomy. • The drug targets NaV1.8 sodium channels in peripheral nerves, offering a novel non-opioid mechanism for pain relief and potentially avoiding the risk of addiction. • While VX-548 was not superior to hydrocodone/acetaminophen in both trials, it showed a similar safety profile and was generally well-tolerated, with manageable side effects. • Vertex plans to submit a New Drug Application to the FDA by mid-year, aiming to provide a new option for acute pain management with a potentially improved safety profile.
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy